Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 55 post-ruxolitinib window

Composite Biomarkers

Post-HSCT Monitoring - 29.6 months

Generated 2026-05-11 07:21 · Post-HSCT Patient

ADSI

Elevated

55.4/100

Autonomic Dysfunction | stable (30-day trend)

Autonomic Dysfunction Severity Index. Higher = more dysfunction.

GVHD Score

Normal

18.5/100

Wearable Activity | worsening (30-day trend)

Composite from HRV, HR, sleep fragmentation, temperature. Ring-derived, not clinical diagnosis.

Recovery

Normal

95.4/100

Trajectory Index | stable (30-day trend)

Overall recovery trajectory. Higher = better.

Pharma

Info

3.0Z

Ruxolitinib Response | stable (30-day trend)

Pharmacodynamic response to ruxolitinib. Z-score relative to pre-treatment baseline.

CV Risk

Elevated

46.9/100

Cardiovascular Composite | stable (30-day trend)

Cardiovascular risk proxy from resting HR, HRV, SpO2. Not equivalent to Framingham or SCORE2.

Allostatic

Normal

1.0/7

Load Score | stable (30-day trend)

Cumulative physiological stress burden. Scale 0-7.

Summary

Post-HSCT Patient | 29.6 months post-HSCT | Ruxolitinib from 2026-03-16

Biomarker	Value	Trend
ADSI	55.4/100	stable (30-day trend)
GVHD_SCORE	18.5/100	worsening (30-day trend)
RECOVERY_INDEX	95.4/100	stable (30-day trend)
CV_RISK	46.9/100	stable (30-day trend)
ALLOSTATIC_LOAD	1.0/7	stable (30-day trend)

HRV (RMSSD)

Significant

129.4% change

p=0.0000, d=1.53 (large)

Lowest HR

Significant

-13.3% change

p=0.0000, d=1.57 (large)

Average HR

Significant

-12.0% change

p=0.0000, d=1.42 (large)

Sleep Efficiency

Significant

3.5% change

p=0.0001, d=0.66 (medium)

Metric	Pre-Rux (mean±SD)	Post-Rux (mean±SD)	Change	p-value	Cohen's d	Effect
HRV (RMSSD)	10.0 ± 2.5 ms	22.9 ± 12.2 ms	+129.4%	0.0000	1.53	large
Lowest HR	76.7 ± 5.7 bpm	66.5 ± 7.4 bpm	-13.3%	0.0000	1.57	large
Average HR	85.2 ± 6.8 bpm	74.9 ± 7.7 bpm	-12.0%	0.0000	1.42	large
Sleep Efficiency	78.6 ± 3.4 %	81.4 ± 5.1 %	+3.5%	0.0001	0.66	medium

Three-Period Trajectory

Pre-acute (2026-02-09) → Post-acute/Pre-Rux → Post-Rux (2026-03-16)

HRV (RMSSD): 8.6 ms → 11.2 ms → 22.9 ms (acute event = inflection, Rux stabilized)

Lowest HR: 79.6 bpm → 74.1 bpm → 66.5 bpm (steady improvement)

Average HR: 88.7 bpm → 82.0 bpm → 74.9 bpm (steady improvement)

Sleep Efficiency: 78.1 % → 79.1 % → 81.4 %

Clinical note: The composite ADSI score dilutes these individual metric signals. While ADSI aggregates multiple domains into a single index, individual metrics like HRV and heart rate show statistically significant pre/post differences that the composite score may obscure through averaging.

Biomarker Dashboard

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – May 09, 2026 · Post-intervention: 55 days (ruxolitinib, March 16)